SE7413484L - - Google Patents

Info

Publication number
SE7413484L
SE7413484L SE7413484A SE7413484A SE7413484L SE 7413484 L SE7413484 L SE 7413484L SE 7413484 A SE7413484 A SE 7413484A SE 7413484 A SE7413484 A SE 7413484A SE 7413484 L SE7413484 L SE 7413484L
Authority
SE
Sweden
Prior art keywords
solid phase
antigen
antibodies
antibody
contacted
Prior art date
Application number
SE7413484A
Other languages
English (en)
Inventor
I Bornstein
A A Kapsalis
Original Assignee
Baxter Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Laboratories Inc filed Critical Baxter Laboratories Inc
Publication of SE7413484L publication Critical patent/SE7413484L/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/804—Radioisotope, e.g. radioimmunoassay
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/819—Multifunctional antigen or antibody
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Materials By The Use Of Magnetic Means (AREA)
SE7413484A 1973-10-26 1974-10-25 SE7413484L (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/410,066 US3949064A (en) 1973-10-26 1973-10-26 Method of detecting antigens or antibodies

Publications (1)

Publication Number Publication Date
SE7413484L true SE7413484L (cs) 1975-04-28

Family

ID=23623067

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7413484A SE7413484L (cs) 1973-10-26 1974-10-25

Country Status (15)

Country Link
US (2) US3949064A (cs)
JP (1) JPS5762020B2 (cs)
AU (1) AU476619B2 (cs)
BE (1) BE820660A (cs)
BR (1) BR7408886A (cs)
CA (1) CA1036493A (cs)
DE (1) DE2450523C3 (cs)
ES (1) ES431413A1 (cs)
FR (1) FR2249334B1 (cs)
GB (1) GB1436934A (cs)
IL (1) IL45707A (cs)
LU (1) LU71027A1 (cs)
NL (1) NL7413552A (cs)
SE (1) SE7413484L (cs)
ZA (1) ZA746098B (cs)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172117A (en) * 1974-05-20 1979-10-23 Biotest-Serum-Institut Gmbh Method for the simultaneous measurement of antigens and their antibodies by solid-phase radioimmunoassay
US4225784A (en) * 1976-06-17 1980-09-30 Smith Kline Instruments, Inc. Covalently bound biological substances to plastic materials and use in radioassay
AT343822B (de) * 1976-08-20 1978-06-26 Immuno Ag Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen
JPS604422B2 (ja) * 1976-10-07 1985-02-04 持田製薬株式会社 抗原の定量方法
USRE34394E (en) * 1978-01-23 1993-09-28 Baxter Diagnostics Inc. Method and composition for double receptor, specific binding assays
JPS608745B2 (ja) * 1978-02-14 1985-03-05 三洋化成工業株式会社 免疫活性物質−つや消しガラス複合体，その製造法及び該複合体を含有してなる測定試薬
US4242322A (en) * 1978-06-07 1980-12-30 Electro-Nucleonics Laboratories, Inc. Methods and materials for detecting antigens and antibodies
US4393040A (en) * 1981-03-24 1983-07-12 Lopapa Institute, Inc. In-vitro diagnostic method for detection of acetylsalicylic acid ingestion
US4994373A (en) 1983-01-27 1991-02-19 Enzo Biochem, Inc. Method and structures employing chemically-labelled polynucleotide probes
ATE23169T1 (de) * 1983-07-21 1986-11-15 Scripps Clinic Res Synthetische polypeptide, die gehirnspezifischen mrnas translatierten proteinoidabschnitten entsprechen, sowie ihre anwendung fuer rezeptoren, methoden und diagnostik.
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
WO1986000991A1 (en) * 1984-07-24 1986-02-13 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5182082A (en) * 1991-01-23 1993-01-26 Becton, Dickinson And Company Multiple aliquot device for distributing a liquid solution into a well
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
US5998220A (en) * 1991-05-29 1999-12-07 Beckman Coulter, Inc. Opposable-element assay devices, kits, and methods employing them
US6168956B1 (en) 1991-05-29 2001-01-02 Beckman Coulter, Inc. Multiple component chromatographic assay device
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US5698686A (en) * 1994-10-20 1997-12-16 Arch Development Corporation Yeast telomerase compositions
US5807552A (en) * 1995-08-04 1998-09-15 Board Of Regents, The University Of Texas System Compositions for conferring immunogenicity to a substance and uses thereof
US5736343A (en) * 1995-08-18 1998-04-07 Landry; Donald Detection of organic compounds through regulation of antibody-catalyzed reactions
US6689757B1 (en) 1996-02-12 2004-02-10 M.L. Laboratories Plc Methods for vaccination and vaccines therefor
US20020034732A1 (en) * 1997-07-30 2002-03-21 Daniel J. Capon Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
EP1343894A4 (en) * 2000-11-02 2005-05-04 Univ Singapore AOPB GENE, PROTEIN, HOMOLOGISTS, FRAGMENTS AND VARIANTS THEREOF, AND THE USE THEREOF FOR PRESENTATION ON THE CELL SURFACE
EP2292762A3 (en) 2002-12-20 2012-12-12 Board of Regents, The University of Texas System VMP-like sequences of pathogenic Borrelia species and strains
CN1820020B (zh) * 2003-05-06 2010-04-28 技术持有有限公司 Sars-冠状病毒病毒样颗粒以及应用方法
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
NZ578657A (en) * 2007-02-02 2012-02-24 Baylor Res Inst Multivariable antigens complexed with targeting humanized monoclonal antibody
NZ578696A (en) 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
NZ589341A (en) * 2007-02-23 2012-02-24 Baylor Res Inst Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
CN102586186A (zh) * 2007-02-23 2012-07-18 贝勒研究院 通过clec-6激活人抗原呈递细胞
JP2010519316A (ja) 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート デクチン−１を介したヒト抗原提示細胞の活性化の治療への応用
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
NZ596171A (en) * 2008-07-16 2012-05-25 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
WO2011127032A1 (en) 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
HUE057713T2 (hu) 2009-04-03 2022-05-28 Univ Chicago A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
EP2588120B1 (en) 2010-07-02 2017-11-15 The University of Chicago Compositions and methods related to protein a (spa) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
EP2633062B1 (en) 2010-10-29 2017-12-27 Life Technologies Corporation Biotin derivatives
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
BR112015006840A2 (pt) 2012-09-27 2017-11-21 Res Found Dev vírus chikungunya atenuado
EP2964254B1 (en) 2013-03-07 2019-09-18 University of Maryland, Baltimore Immunotherapeutic potential of modified lipooligosaccharides/lipid a
US10993990B2 (en) 2014-05-16 2021-05-04 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
JP7640466B2 (ja) 2019-03-27 2025-03-05 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル Ｃｄ４０活性化特性を有する組換えタンパク質
EP4061835A1 (en) 2019-11-21 2022-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2021228836A1 (en) 2020-05-13 2021-11-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with ox40 activating properties
US20250177514A1 (en) 2022-01-28 2025-06-05 Pfizer Inc. Coronavirus antigen variants
WO2025017036A1 (en) 2023-07-17 2025-01-23 Institut National de la Santé et de la Recherche Médicale Alphavirus nsp3 helical tubular scaffolds
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (cs) * 1967-05-23 1971-08-02 Pharmacia Ab
SE343210B (cs) * 1967-12-20 1972-03-06 Pharmacia Ab
US3646346A (en) * 1968-12-26 1972-02-29 Pharmacia Ab Antibody-coated tube system for radioimmunoassay
US3867517A (en) * 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies

Also Published As

Publication number Publication date
NL7413552A (nl) 1975-04-29
AU476619B2 (en) 1976-09-30
BR7408886A (pt) 1976-05-04
DE2450523B2 (de) 1976-10-07
DE2450523A1 (de) 1975-05-22
CA1036493A (en) 1978-08-15
FR2249334B1 (cs) 1977-03-25
ES431413A1 (es) 1976-10-16
IL45707A0 (en) 1974-11-29
BE820660A (fr) 1975-02-03
GB1436934A (en) 1976-05-26
JPS5762020B2 (cs) 1982-12-27
US3949064A (en) 1976-04-06
FR2249334A1 (cs) 1975-05-23
DE2450523C3 (de) 1978-06-22
JPS5075095A (cs) 1975-06-20
AU7378774A (en) 1976-04-01
USRE29955E (en) 1979-04-03
ZA746098B (en) 1975-11-26
LU71027A1 (cs) 1975-04-17
IL45707A (en) 1977-01-31

Similar Documents

Publication Publication Date Title
SE7413484L (cs)
ATE1614T1 (de) Immunologisches bestimmungsverfahren.
AU498364B2 (en) Assaying antibody, antigen or antibody-antigen complex in fluid sample
NL176307C (nl) Werkwijze voor het bepalen van antigeenconcentraties door radio- immunoanalyse.
SE7709232L (sv) Forfarande och anordning for bestemning av antigener och antikroppar
SE7904386L (sv) Biologisk provmetod med utnyttjande av fast fas
SE8102558L (sv) Immunologisk bestemmningsmetod
IT1177121B (it) Metodo per determinare i complessi immuni nel siero
SE8200978L (sv) Forfarande och medel for immunologisk analys
EP0089008A3 (en) Method for the combined immunological determination of procollagen peptide (type iii) and procollagen peptide col 1 (type iii), and method for the production of anti-procollagen peptide col 1 (type iii) serum
GB1475125A (en) Immunological detection
ES557705A0 (es) Dispositivo para determinacion de una substancia presente en una muestra
NO175657C (no) Fremgangsmåte for utförelse av en immunologisk bestemmelse av et antigen i en væskepröve samt reagens for bruk til dette
SE7602834L (sv) Diagnotiskt reagenssystem
DK196282A (da) Fremgangsmaade samt kit til bestemmelse af antistoffer mod oploeselige antigener
KR850002385A (ko) PIVKA-Ⅱ의 측정(assay)용 방법 및 시약
GB1526914A (en) System for rate immunonephelometric analysis
ATE16219T1 (de) Immunologisches latex-agglutinationsverfahren.
NL167519C (nl) Werkwijze voor het bepalen volgens een radio-immuno- proef van de aanwezigheid van neisseria-gonorrhoeae- antilichamen in serum van de mens.
NL7606248A (nl) Werkwijze voor het aantonen van anti-lichamen in lichaamsvloeistoffen door middel van beken- de antigenen of voor het bepalen van antigenen door middel van uit lichaamsvloeistoffen afkom- stige antilichamen.
ES8504257A1 (es) Un metodo para determinar antigenos estreptococales en una muestra clinica
DE3568639D1 (en) Method for the determination of a substance capable of immunological binding
GB1549921A (en) Process for quantitative determination of antigen or antibody
JPS52110820A (en) Microanalysis of antigen protein by estimating immunity for enzyme antibody
ES8608321A1 (es) Hibridomas productores de anticuerpos monoclonales especifi-cos para la inmunoglobulina e (ige)humana del mieloma ns

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 7413484-2